90Y微球的研发现状与应用研究

doi:10.7538/tws.2022.35.03.0189

摘要/Abstract

摘要： ⁹⁰Y微球将放射性微球通过微创介入灌注至肿瘤供血动脉，放射性微球随血流分散并滞留在肿瘤末端小血管，通过持续释放高能射线实现高选择性地杀伤肿瘤细胞，对中晚期肝癌的局部治疗具有重要价值。目前全球已上市两款⁹⁰Y微球产品（SIR-Spheres-和TheraSpheres-），在国外已开展近二十年临床应用，纳入多个权威肝癌诊疗规范和指南。自2018年开始，SIR-Spheres-和TheraSpheres-逐步进入我国，引起国内临床专家的关注，并被纳入我国最新的肝癌诊疗相关指南。2022年，SIR-Spheres-作为进口药品通过国家药监局审批上市，用于标准治疗失败且不可手术切除的结直肠癌肝转移患者的治疗。同期完成首例TheraSpheres-治疗原发性肝癌。我国自主研发的90Y炭微球显示良好的临床转化潜力。为更好开展⁹⁰Y微球产品在我国临床研究与应用，推动同类产品研发创新，本文对⁹⁰Y微球的种类与研发现状、临床应用，以及在国内的发展情况和展望进行综述，以期为我国90Y微球药物的研发与应用提供参考。

关键词: ⁹⁰Y, 微球, 原发性肝癌, 转移性肝癌, 研发现状

Abstract: With⁹⁰Y microspheres, radioactive microspheres are perfused to tumor feeding arteries through minimally invasive intervention, and then diffused and retained in small vessels of tumor terminals along with blood flow, so as to high selectively kill tumor cells by means of sustained release of high energy rays. ⁹⁰Y microspheres are of important value in the local treatment of advanced liver cancer. At present, two types of 90Y microsphere products (SIR-Spheres- and TheraSpheres-) which have appeared on the market globally, have been clinically applied abroad for nearly twenty years, and have been incorporated into many authoritative norms and guidelines for the diagnosis and treatment of liver cancer. Since 2018, SIR-Spheres- and TheraSpheres- have gradually entered China and attracted the attention of domestic clinical experts, and have been incorporated into the latest relevant guidelines for the diagnosis and treatment of liver cancer in China. In 2022, SIR-Spheres-, as imported drugs, passed the approval of the National Medical Products Administration (NMPA) and were approved for listing to treat patients with surgically unresectable liver metastases of colorectal cancer after failure in standard treatment. At the same time, the first case of primary liver cancer has been treated by TheraSpheres-. ⁹⁰Y carbon microspheres independently researched and developed in China show good clinical conversion potential. In order to more effectively carrying out clinical research and application of 90Y microsphere products in China and promote research and development innovation of similar products, this paper reviews types, the research and development status, clinical application and domestic development and outlook of ⁹⁰Y microspheres, so as to provide reference for the research, development and application of ⁹⁰Y microsphere drugs in China.

Key words: Yttrium-90, microspheres, primary liver cancer, metastatic liver cancer, research and development status

高洁, 刘晓明, 周文华, 王红亮, 赵小生, 葛强, 李建国. ⁹⁰Y微球的研发现状与应用研究[J]. 同位素, 2022, 35(3): 189-199.

GAO Jie, LIU Xiaoming, ZHOU Wenhua, WANG Hongliang, ZHAO Xiaosheng, GE Qiang, LI Jianguo. Study on Research and Development Status and Application of ⁹⁰Y Microspheres[J]. Journal of Isotopes, 2022, 35(3): 189-199.

参考文献

［1］Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA: A cancer Journal for Clinicians, 2021, 71(3): 209-249.
［2］许颖. 内放射治疗肝细胞癌［J］. 世界临床药物,2011,32(12):742-747.
Xu Ying. Radionuclide therapy of hepatocellular carcinoma［J］.World Clinical Drugs, 2011, 32(12): 742-747(in Chinese).
［3］王姗，吴庆旺，李小科，等. 《原发性肝癌诊疗规范（2019年版）》［J］. 中国实用外科杂志,2020(2):121-138.
［4］中国临床肿瘤学会(CSCO). 原发性肝癌诊疗指南［M］. 北京：人民卫生出版社，2020.
［5］Heimbach J K, Kulik L M, Finn R S, et al. AASLD guidelines for the treatment of hepatocellular carcinoma［J］. Hepatology, 2018, 67(1): 358-380.
［6］Galle P R, Forner A, Llovet J M, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma［J］. J Hepatol, 2018, 69(1): 182-236.
［7］Omata M, Cheng A L, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update［J］.Hepatol Int, 2017, 11(4): 317-370.
［8］Ehrhardt G J , Day D E . Therapeutic use of 90Y microspheres［J］. International Journal of Radiation Applications & Instrumentation.part B.nuclear Medicine & Biology, 1987, 14(3): 233-242.
［9］邱怀明,漆剑频. 90钇玻璃微球内放射治疗原发性肝癌的临床研究［J］. 放射学实践,2004,19(9):654-657.
Qiu Huaiming, Qi Jianpin. Interventional treatment of primary liver cancer with intrahepatic 90 Y glass microspheres［J］. Radiol Practice , 2004, 19(9): 654-657(in Chinese).
［10］Houle S, Kip T C K, Rotstein L E, et al. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres［J］. Radiology, 1989, 172(3): 857-860.
［11］黄文塰,林武军,吴兆悦,等. 含钇玻璃微球的研制和应用［J］. 上海建材学院学报,1992(4):347-352.
Huang Wenhai, Lin Wujun, Wu Zhaorui, et al.Preparation and application of 90-Y glass microspheres［J］.Journal of SHANGHAI Institute of Building Materials, 1992(4): 347-352(in Chinese).
［12］黄文塰,钱达兴,周萘，等. 辐射治疗玻璃微球的制备与应用［J］. 玻璃与搪瓷，2002，30（2）：13-16.
Huang Wenhai, Qian Daxing, Zhou Nai ,et al. Preparation and application of glass microspheres for radiotherapy［J］. Class Enamel & Ophthalmic Optics, 2002, 30 (2): 13-16(in Chinese).
［13］Dillehay L E, Mayer R, Zhang Y G, et al. Use of bremsstrahlung radiation to monitor Y-90 tumor and whole body activities during experimental radioimmunotherapy in mice［J］. Cancer, 1994, 73(3): 945-950.
［14］Poorbaygi H, Reza Aghamiri S M, Sheibani S, et al. Production of glass microspheres comprising ⁹⁰Y and ¹⁷⁷Lu for treating of hepatic tumors with SPECT imaging capabilities［J］. Appl Radiat Isot, 2011, 69(10): 1407-1414.
［15］Jernigan S R, Osborne J A, Mirek C J, et al. Selective internal radiation therapy: quantifying distal enetration and distribution of resin and glass microspheres in a surrogate arterial model［J］. J Vasc Interv Radiol, 2015, 26: 897-904.
［16］Simon N, Siffert R, Baron M G, et al. Preoperative irradiation of osteogenic sarcoma with intra-arterially injected yttrium-90 microspheres: Case report［J］. Cancer, 1968, 21(3): 453-455.
［17］Gulec S A, Siegel J A. Posttherapy radiation safety considerations in radiomicrosphere treatment with ⁹⁰Y-Microspheres［J］. The Journal of Nuclear Medicine, 2007, 12(48): 2080-2086.
［18］Gray B N, Anderson J E, Burton M A, et al. Regression of liver metastases following treatment with yttrium-90 microspheres［J］. The Australian and New Zealand journal of surgery, 1992, 62(2): 105-110.
［19］Subramanian S, Pandey U, Chaudhari P, et al. Preliminary evaluation of indigenous ⁹⁰Y-labelled microspheres for therapy of hepatocellular carcinoma［J］. Indian J Med Res, 2016, 143: 74-81.
［20］Murthy R, Xiong H, Nunez R, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results［J］. J Vasc Interv Radiol, 2005, 16: 937-945.
［21］Ahmadzadehfar H, Meyer C, Pieper C C, et al. Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5% glucose during administration［J］. EJNMMI, 2015, 5: 54.
［22］Pieper C C, Willinek W A, Thomas D, et al. Incidence and risk factors of early arterial blood flow stasis during first radioembolization of primary and secondary liver malignancy using resin microspheres: an initial single-center analysis［J］. European Radiology, 2016, 26(8): 2779-2789.
［23］Piana P M, Bar V, Doyle L, et al. Early arterial stasis during resin based yttrium-90 radioembolization: Incidence and preliminary outcomes［J］. HPB (Oxford), 2014, 16: 336-341.
［24］Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization［J］. Frontiers in Oncology, 2014, 4(4): 198.
［25］Nakakuma K, Tashiro S, Hiraoka T, et al. Hepatocellular carcinoma and metastatic cancer detected by iodized oil［J］. Radiology, 1985, 154(1): 15-17.
［26］Yumoto Y, Jinno K, Tokuyama K, et al. Hepatocellular carcinoma detected by iodized oil［J］. Radiology, 1985, 154(1): 19-24.
［27］Wang S J, Lin W Y, Lui W Y, et al. Hepatic artery injection of Yttrium-90-lipiodol: biodistribution in rats with hepatoma［J］. J Nucl Med, 1996, 37(2): 332-335.
［28］Mu P Y, Jiang X L, Chen J, et al. Research on extracted ⁹⁰Y with ²⁰⁴P in lipiodol for liver cancer［J］. Journal of Radioanalytical and Nuclear Chemistry, 2007, 272(3): 669-671.
［29］Bouvry C, Ardisson V, Noiret N, et al. Labeling of hinokitiol with 90Y for potential radionuclide therapy of hepatocellular carcinoma［J］. Processes, 2021, 9(6): 940.
［30］Qiao T J, Sun G F. Study on microbial safety of ozone/biological activated carbon process［J］. China Water & Wastewater, 2008, 24(5): 31-39.
［31］Lu S, Sun Y, Chen C. Adsorption of radionuclides on carbon-based nanomaterials［J］. Interface Science and Technology, 2019, 29: 141-215.
［32］Pinto M A, Pereira A T, Gon-alves I C. 1.3.5-carbon biomaterials, biomaterials science (fourth edition)［J］. Academic Press, 2020: 327-360.
［33］Rudolf P, Sabrina S, Gabriele D, et al. Single dose activated charcoal for gut decontamination: application by medical non-professionals-a prospective study on availability and practicability［J］. Toxicology Reports, 2017, 4: 49-54.
［34］Wollner I, Knutsen C A, Ullrich K A, et al. Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs［J］. Cancer Research, 1987, 47: 3285-3290.
［35］张锦明,田嘉禾,曹丽敏,等. 肿瘤内照射治疗剂:⁹⁰Y-活性碳的实验研究［J］. 核技术,2001,24(11):937-940.
Zhang Jinming, Tian Jiahe, Cao Limin, et al. ⁹⁰Y Charcoal as a new agent for internal radiotherapy［J］. Nuclear Techniques, 2001, 24(11): 937-940（in Chinese）.
［36］赵小生,张驰翔,路静,等. 负载金属核素的炭微球及制备方法和应用:中国,CN111939276A［P］. 2020.
［37］Kawashita M, Shineha R, Kim H M, et al. Preparation of ceramic microspheres for in situ radiotherapy of deep-seated cancer［J］. Biomaterials, 2003, 24(17): 2955-2963.
［38］Nosrati Z, Khanchi A R, Sheybani S. Preparation of low-density⁹⁰Y microspheres consisting of mesoporous silica core/yttria shell: a potential therapeutic agent for hepatic tumors［J］. J Radioanal Nucl Chem, 2014, 301(2): 373-382.
［39］Watanabe N, Oriuchi N, Endo K, et al. Yttrium-90-labeled human macroaggregated albumin for internal radiotherapy: combined use with DTPA［J］. Nucl Med Biol, 1999, 26: 847-851.
［40］Hafeli U O, Sweeney S M, Beresford B A, et al. Magnetically directed poly (lactic acid) ⁹⁰Y-microspheres: novel agents for targeted intra cavity radiotherapy［J］. J Biomed Mater Res, 1994, 28: 901-908.
［41］宋莉, 邹英华. 钇90微球管理专家共识［J］. 中国介入影响与治疗学,2021,18(6):321-324.
Song Li, Zou Yinghua. Experts consensus on management of yttrium-90 microspheres［J］. Chin J Interv Imaging Ther, 2021, 18(6): 321-324(in Chinese).
［42］文天夫. 原发性肝癌诊疗规范(2017年版)解读［J］. 中国普外基础与临床杂志,2018,25(1):32-34.
Wen Tianfu. Interpretation of guidelines for diagnosis and treatment of primary liner cancer in Cina(2017 edition)［J］.Chinese Journal of Bases and Clinics in General Surgery, 2018, 25(1): 32-34(in Chinese).
［43］程树群,卫旭彪. 肝细胞癌伴门静脉癌栓的降期治疗［J］. 临床肝胆病杂志,2020,36(2):263-266.
Cheng Shuqun, Wei Xubiao. Downstaging treatment of hepatocellular carcinoma with portal vein tumor thrombus［J］. Journal of Clinical Hepatology, 2020, 36(2): 263-266(in Chinese).
［44］贾中芝. 钇-90微球放射栓塞治疗不可切除的神经内分泌肿瘤肝转移的meta分析［J］. 中华普通外科杂志,2019,34(11):979-982.
Jia Zhongzhi.Meta-analysis of Y-90 microsphere radiation embolization for liver metastasis of unresectable neuroendocrine tumors［J］. Chinese Journal Gen Surg, 2019, 34(11): 979-982(in Chinese).
［45］Riaz A, Gabr A, Abouchaleh N, et al. Radioembolization for hepatocellular carcinoma: statistical confirmation of improved survival in responders by landmark analyses［J］. Hepatology, 2018, 67: 873-883.
［46］Salem R, Gordon A C, Mouli S, et al. 90Y radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma［J］. Gastroenterology, 2016, 151: 1155-1163.
［47］Garlipp B, de Baere T, Damm R, et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization［J］. Hepatology, 2014, 59: 1864-1873.
［48］杨志,林岩松. 钇-90（⁹⁰Y）微球选择性内放射治疗原发性和转移性肝癌的中国专家共识［J］. 中华肝脏病杂志,2021,29(7):648-658.
Yang Zhi, Lin Yansong. Chinese expert consensus on selective internal radiation therapy with yttrium-90 for primary and metastatic hepatocellular carcinoma［J］. Chinese Journal of hepatology, 2021, 29(7): 648-658(in Chinese).
［49］Padia S A, Lewandowski R J, Johnson G E, et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions［J］. J Vasc Interv Radiol, 2017, 28: 1-15.
［50］Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation［J］. Hepatology, 2011, 54(3): 868-878.
［51］Meyer C, Pieper C C, Ahmadzadehfar H, et al. Yttrium-90 radioembolization of unresectable hepatocellular carcinoma-a single center experience［J］. Oncotargets and Therapy, 2017, 10: 4773-4785.
［52］Tabone M, Calvo A, Russolillo N, et al. Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience［J］. Journal of Gastrointestinal Oncology, 2020, 11(1):84-90.
［53］叶颖江,申占龙,王杉. 转移性肝癌的治疗理念和策略［J］. 中华普外手术学杂志,2014,8(1):26-29.
Ye Yinjiang, Shen Zhanlong, Wang bin. Treatment concept and strategy of metastatic liver cancer［J］. Chinese Journal of Surgical Surgery 2014, 8(1): 26-29(in Chinese).
［54］李慕行,吕毅. 钇-90微球放疗栓塞在原发性肝癌治疗中的应用［J］. 现代肿瘤医学, 2013,21(12):2859-2863.
Li Muxing, Lv Yi. Therapeutic value of Yttrium90 microsphere in the treatment of primary liver cancer［J］ Modern Oncology, 2013, 21(12): 2859-2863(in Chinese)
［55］Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-spheres plus chemotherapy vs chemotherapy alone for treating patients with liver metastases from primary large bowel cancer［J］. Ann Oncol, 2001, 12(12): 1711-1720.
［56］Marsala A, Lee E W, Padia S A. Yttrium-90 radioembolization for metastatic colorectal cancer: outcomes by number of lines of therapy［J］. Semin Intervent Radiol, 2017, 34(2): 116-120.
［57］Van Hazel G, Blackell A, Anderon J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/ leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer［J］. J Surg Oncol, 2004, 88(2): 78-85.
［58］Chauhan N, Mulcahy M F, Salem R, et al. Thera sphere yttrium-90 glass microspheres combined with chemotherapy versus chemotherapy alone in second-line treatment of patients with metastatic colorectal carcinoma of the liver: protocol for the EPOCH phase 3 randomized clinical trial［J］. JMIR Res Protoc, 2019, 8(1): e1545.
［59］刘瑞青,贾中芝,曹会存,等. 钇-90微球在治疗手术不可切除且化疗耐药的结直肠癌肝转移中的应用——钇-90微球放射栓塞系列回顾(七)［J］. 介入放射学杂志,2018,27(10):1003-1010.
Liu Ruiqing, Jia Zhongzhi, Cao Huicun, et al. The roie of yttrium-90 radioembolization in the treatment of unresectable, chemorefractory colorectal cancer liver metastases. A series review of radioembolization with yttrium-90 microspheres(part Ⅶ)［J］. J Intervent Radiol, 2018, 27(10): 1003-1010(in Chinese)
［60］郑丽丽,贾中芝,王斯妮,等. 钇-90微球放射栓塞治疗肝脏恶性肿瘤的不良反应和并发症——钇-90微球放射栓塞系列回顾(五)［J］. 介入放射学杂志,2018,27(2):190-196.
Zheng Lili, Jia Zhongzhi, Wang Sini,et al. Side effects and complications of yttrium-90 radioembolization therapy for hepatic malignancies. Aseries review of radioembolization with 90Y microspheres （part Ⅴ）［J］. J Intervent Radiol, 2018, 27(2): 190-196(in Chinese).
［61］李绍钦,顾晓诚,贾中芝. 钇90微球栓塞治疗不可切除的神经内分泌肿瘤肝转移［J］. 中华肝胆外科杂志,2016,22(5):355-357.
Li Shaoqin, Gu Xiaocheng, Jia Zhongzhi. Yttriam. 90 radioembolization for unresectable neuroendocrine tumor liver metastases［J］. Chinese Journal Hepatobiliary Surg, 2016, 22(5): 355-357(in Chinese).
［62］程树群,孙居仙,石洁,等. 肝细胞癌伴门静脉癌栓的治疗现状［J］. 中国普外基础与临床杂志,2015,22(10):1157-1160.
Chen Shuqun, Sun Juxian, Shi jie, et al. Status of treatment of hepatocellular carcinoma with portal vein thrombus［J］. Chinese Journal of Bases and Clinics in General Surgery, 2015, 22(10): 1157-1160(in Chinese).
［63］贾中芝,朱春富,徐后云. 钇-90微球放射栓塞治疗肝细胞性肝癌伴门静脉癌栓的安全性与疗效评价［J］. 中华普通外科杂志,2019,34(5):439-443.
Jia Zhongzhi, Zhu Chunfu, Xu Houyun. The safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis［J］. Chin J Gen Surg, 2019, 34(5): 439-443(in Chinese).
［64］Pracht M, Edeline J, Lenoir L, et al. Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: preliminary results［J］. International Journal of Hepatology, 2013, 2(17): 827649.
［65］Ruohoniemi D M, Zhan C Y, Wei J, et al. Safety and effectiveness of yttrium-90 radioembolization around the time of immune checkpoint inhibitors for unresectable hepatic metastases［J］. Journal of Vascular and Interventional Radiology, 2020, 31( 8): 1233-1241.
［66］Chew V, Lee Y H, Pan L, et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma［J］. Gut, 2018: 1-12.
［67］Kim K J, Kim J H, Lee S J, et al. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model［J］. Oncotarget, 2017, 8(25): 41242-41255.
［68］Klee E W, Goyal L, Dugan M, et al. Y-90 Radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma［J］. Cardiovasc Intervent Radiol, 2018, 41(11): 1-4.
［69］Zhan C Y, Ruohoniemi D, Shanbhogue K P, et al. Safety of combined Yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma［J］. Journal of Vascular and Interventional Radiology, 2019, 31(1):1-10.
［70］郑荣寿,孙可欣,张思维,等. 2015年中国恶性肿瘤流行情况分析［J］. 中华肿瘤杂志,2019,41(1):19-28.
Zheng Rongshou, Sun Kexin, Zhang Siwei, et al. Report of cancer epidemiology in China, 2015［J］. Chinese Journal of Oncology, 2019, 41(1): 19-28(in Chinese).

[1]	耿自胜, 李波, 吴建荣, 陈云明, 罗宁, 孙志中, 曾俊杰, 张劲松. 基于聚锑酸的双柱型⁹⁰Sr-⁹⁰Y发生器研制[J]. 同位素, 2022, 35(3): 224-232.
[2]	尹帮顺, 邓启民, 潘俊男, 程作用. 水合氧化锰用于⁹⁰Y发生器的制备[J]. 同位素, 2021, 34(6): 525-530.
[3]	尹帮顺, 邓启民, 潘俊男, 程作用. 强碱性阴离子交换树脂用于⁹⁰YCl₃溶液金属杂质的纯化[J]. 同位素, 2021, 34(6): 549-555.
[4]	于雪;何虎;武伟名;罗志福. ⁹⁰Sr/⁹⁰Y源的应用及制备[J]. 同位素, 2015, 28(3): 189-192.
[5]	李丽波;官国英;刘中瑞;侯惠仁;梁瑞鹏. β₂-微球蛋白酶联免疫分析试剂盒的研制[J]. 同位素, 2012, 25(3): 175-178.
[6]	李云春;谭天秩;莫廷树;卢武胜;邓候富;杨晓川. 利卡汀的人体显像和组织分布 [J]. 同位素, 2007, 20(3): 135-140.
[7]	作者. RIA检测AFP对肝源性疾病的临床诊断价值 [J]. 同位素, 2003, 16(1 ): 54-54 .
[8]	作者. β_2-MG、AlbRIA在肾病诊断中的应用 [J]. 同位素, 2001, 14(2 ): 119-119 .
[9]	作者. 固相微球法人IgG放射免疫分析试剂盒的研制 [J]. 同位素, 2000, 13 (4 ): 223-223 .
[10]	作者. 明胶微球控释示踪研究 [J]. 同位素, 1998, 11 (3 ): 41-44 .
[11]	作者. ~(90)Y、~(32)P-GTMS 介入治疗恶性肿瘤的实验研究与初步临床应用 [J]. 同位素, 1998, 11 (2 ): 43-49 .
[12]	作者. ~(153)Sm-树脂微球的制备和兔股骨血流量测定 [J]. 同位素, 1998, 11 (1 ): 40-44 .
[13]	作者. 30 例 AFP 阴性原发性肝癌患者 CEA 和 CA50 联合检测探讨 [J]. 同位素, 1997, 10 (2 ): 61-63 .
[14]	作者. 血清CEA、SF、β_2-MG RIA联合检测对肺癌诊断及疗效观察的临床价值 [J]. 同位素, 1997, 10 (1 ): 41-42+4.
[15]	作者. 血、尿α1─微球蛋白和尿白蛋白联合检测对肾功能的评价 [J]. 同位素, 1996, 9 (2 ): 39-42 .

⁹⁰Y微球的研发现状与应用研究

Study on Research and Development Status and Application of ⁹⁰Y Microspheres

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics